Competitive AdvantageEmpaveli is the only treatment that offers greater efficacy with proteinuria reduction, eGFR, and C3 deposition, which are the goals that clinicians have long sought to accomplish.
Market PotentialLaunch in IC-MPGN and C3G have significant potential and could ultimately become a blockbuster.
Product EffectivenessEmpaveli maintains significant proteinuria reduction regardless of immunosuppressant use or baseline proteinuria levels.